- Biologics technology transfers carry 3× the regulatory complexity of small-molecule transfers
- Process characterisation at the sending site is the single most important success factor
- Analytical method transfer must precede process transfer - not run in parallel
- A milestone-based governance model reduces transfer timeline by 25–35% vs. activity-based planning
Technology transfer in biologics manufacturing is one of the most complex undertakings in the pharmaceutical industry. Unlike small-molecule transfers, where the process is typically well-characterised and transferable through documented procedures, biologics processes are inherently variable - tied to cell lines, fermentation conditions, and purification sequences that require extensive comparability evidence to satisfy regulatory authorities.
A biologic technology transfer involves four overlapping domains: (1) process knowledge transfer - ensuring that all critical process parameters (CPPs) and their acceptable ranges are fully documented and understood at the receiving site; (2) analytical method transfer - confirming that the receiving site's laboratory can accurately reproduce the analytical methods used to release and characterise the product; (3) regulatory package alignment - updating drug master files, site master files, and marketing authorisation variations to reflect the new site; and (4) supply continuity management - maintaining product availability during the transfer window, which typically spans 18–36 months for biologics.
Based on SCPS Experts' involvement in multiple biologic technology transfer programs, the three most critical success factors are: first, comprehensive process characterisation at the sending site before transfer activities begin - gaps in this documentation are the leading cause of transfer failures; second, a sequential (not parallel) approach to analytical and process transfer, ensuring that product quality can be reliably measured before process performance is assessed; and third, a milestone-based governance model with clear go/no-go criteria at each phase, enabling proactive risk management rather than reactive problem-solving.
In a recent monoclonal antibody manufacturing transfer from a European innovator to a CDMO in North Africa, SCPS Experts' 4-phase methodology enabled the successful completion of process performance qualification (PPQ) batches within 22 months - 4 months ahead of the original project plan. Regulatory submissions were filed simultaneously in Europe and the target market, with no critical findings during the health authority review.